Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael Pearl

Showing results (11-20 of 14) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 14 results.
Radiology|January 5, 2017
Utility of PET/CT to Evaluate Retroperitoneal Lymph Node Metastasis in High-Risk Endometrial Cancer: Results of ACRIN 6671/GOG 0233 TrialMostafa Atri, Zheng Zhang, Farrokh Dehdashti, et al.
Gynecologic Oncology|March 27, 2016
Tumor mutational analysis of GOG248, a phase II study of temsirolimus or temsirolimus and alternating megestrol acetate and tamoxifen for advanced endometrial cancer (EC): An NRG Oncology/Gynecologic Oncology Group studyAndrea P Myers, Virginia L Filiaci, Yuping Zhang, et al.
Cancer Research|October 19, 2006
Activation of EDTA-resistant gelatinases in malignant human tumorsDonghai Chen, Alanna Kennedy, Jaw-Yuan Wang, et al.
Gynecologic Oncology|January 25, 2014
Temsirolimus with or without megestrol acetate and tamoxifen for endometrial cancer: a gynecologic oncology group studyGini F Fleming, Virginia L Filiaci, Brandon Marzullo, et al.
Pageof 2

Showing results (11-20 of 14) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 14 results.
Radiology|January 5, 2017
Utility of PET/CT to Evaluate Retroperitoneal Lymph Node Metastasis in High-Risk Endometrial Cancer: Results of ACRIN 6671/GOG 0233 TrialMostafa Atri, Zheng Zhang, Farrokh Dehdashti, et al.
Gynecologic Oncology|March 27, 2016
Tumor mutational analysis of GOG248, a phase II study of temsirolimus or temsirolimus and alternating megestrol acetate and tamoxifen for advanced endometrial cancer (EC): An NRG Oncology/Gynecologic Oncology Group studyAndrea P Myers, Virginia L Filiaci, Yuping Zhang, et al.
Cancer Research|October 19, 2006
Activation of EDTA-resistant gelatinases in malignant human tumorsDonghai Chen, Alanna Kennedy, Jaw-Yuan Wang, et al.
Gynecologic Oncology|January 25, 2014
Temsirolimus with or without megestrol acetate and tamoxifen for endometrial cancer: a gynecologic oncology group studyGini F Fleming, Virginia L Filiaci, Brandon Marzullo, et al.
Pageof 2